Development of a pentylenetetrazole-induced seizure model to evaluate kinase inhibitor efficacy in the central nervous system

Neuroscience Letters

Volumn 395, Issue 2, 2006, Pages 143-148

  Morgan, Louise ^a   Neame, Stephen J ^a   Child, Hannah ^a   Chung, Raymond ^a   Shah, Bina ^a   Barden, Laura ^a   Staddon, James M ^a   Patel, Toshal R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cell signalling; Epilepsy; Inhibitor; JNK; Pentylenetetrazole; Phosphatase

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ENZYME ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; PENTETRAZOLE; PHOSPHOTRANSFERASE INHIBITOR; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DRUG EFFICACY; HIPPOCAMPUS; IMMUNOPRECIPITATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SEIZURE; SIGNAL TRANSDUCTION;

ANIMALS; CONVULSANTS; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME ACTIVATION; HIPPOCAMPUS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MAP KINASE KINASE 4; MICE; MICE, INBRED C57BL; PENTYLENETETRAZOLE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-JUN; SEIZURES;

EID: 31944432564     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2005.10.068     Document Type: Article

References (21)

1. B.L. Bennett, D.T. Sasaki, B.W. Murray, E.C. O'Leary, S.T. Sakata, W. Xu, J.C. Leisten, A. Motiwala, S. Pierce, Y. Satoh, S.S. Bhagwat, A.M. Manning, and D.W. Anderson SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase Proc. Natl. Acad. Sci. U.S.A. 98 2001 13681 13686
2. S. Brecht, R. Kirchhof, A. Chromik, M. Willesen, T. Nicolaus, G. Raivich, J. Wessig, V. Waetzig, M. Goetz, M. Claussen, D. Pearse, C.Y. Kuan, E. Vaudano, A. Behrens, E. Wagner, R.A. Flavell, R.J. Davis, and T. Herdegen Specific pathophysiological functions of JNK isoforms in the brain Eur. J. Neurosci. 21 2005 363 377
3. S. Carboni, A. Hiver, C. Szyndralewiez, P. Gaillard, J.P. Gotteland, and P.A. Vitte AS601245 (1,3-benzothiazol-2-yl (2-[[2-(3-pyridinyl) ethyl] amino]-4 pyrimidinyl) acetonitrile): a c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties J. Pharmacol. Exp. Ther. 310 2004 25 32
4. Y.R. Chen, and T.H. Tan The c-Jun N-terminal kinase pathway and apoptotic signaling Int. J. Oncol. 16 2000 651 662
5. E.T. Coffey, G. Smiciene, V. Hongisto, J. Cao, S. Brecht, T. Herdegen, and M.J. Courtney c-Jun N-terminal protein kinase (JNK) 2/3 is specifically activated by stress, mediating c-Jun activation, in the presence of constitutive JNK1 activity in cerebellar neurons J. Neurosci. 22 2002 4335 4345
6. A. Eilers, J. Whitfield, C. Babij, L.L. Rubin, and J. Ham Role of the Jun kinase pathway in the regulation of c-Jun expression and apoptosis in sympathetic neurons J. Neurosci. 18 1998 1713 1724
7. K.A. Gallo, and G.L. Johnson Mixed-lineage kinase control of JNK and p38 MAPK pathways Nat. Rev. Mol. Cell. Biol. 3 2002 663 672
8. Q.H. Guan, D.S. Pei, Q.G. Zhang, Z.B. Hao, T.L. Xu, and G.Y. Zhang The neuroprotective action of SP600125, a new inhibitor of JNK, on transient brain ischemia/reperfusion-induced neuronal death in rat hippocampal CA1 via nuclear and non-nuclear pathways Brain Res. 1035 2005 51 59
9. S. Gupta, T. Barrett, A.J. Whitmarsh, J. Cavanagh, H.K. Sluss, B. Derijard, and R.J. Davis Selective interaction of JNK protein kinase isoforms with transcription factors EMBO J. 15 1996 2760 2770
10. J. Ham, C. Babij, J. Whitfield, C.M. Pfarr, D. Lallemand, M. Yaniv, and L.L. Rubin A c-Jun dominant negative mutant protects sympathetic neurons against programmed cell death Neuron 14 1995 927 939
11. J. Ham, A. Eilers, J. Whitfield, S.J. Neame, and B. Shah c-Jun and the transcriptional control of neuronal apoptosis Biochem. Pharmacol. 60 2000 1015 1021
12. T. Herdegen, F.X. Claret, T. Kallunki, A. Martin-Villalba, C. Winter, T. Hunter, and M. Karin Lasting N-terminal phosphorylation of c-Jun and activation of c-Jun N-terminal kinases after neuronal injury J. Neurosci. 18 1998 5124 5135
13. S. Hunot, M. Vila, P. Teismann, R.J. Davis, E.C. Hirsch, S. Przedborski, P. Rakic, and R.A. Flavell JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease Proc. Natl. Acad. Sci. U.S.A. 101 2004 665 670
14. C.Y. Kuan, A.J. Whitmarsh, D.D. Yang, G. Liao, A.J. Schloemer, C. Dong, J. Bao, K.J. Banasiak, G.G. Haddad, R.A. Flavell, R.J. Davis, and P. Rakic A critical role of neural-specific JNK3 for ischemic apoptosis Proc. Natl. Acad. Sci. U.S.A. 100 2003 15184 15189
15. U.K. Laemmli Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature 227 1970 680 685
16. A.M. Manning, and R.J. Davis Targeting JNK for therapeutic benefit: from junk to gold? Nat. Rev. Drug Discov. 2 2003 554 565
17. G.V. Putcha, K.L. Moulder, J.P. Golden, P. Bouillet, J.A. Adams, A. Strasser, and E.M. Johnson Induction of BIM, a proapoptotic BH3-only BCL-2 family member, is critical for neuronal apoptosis Neuron 29 2001 615 628
18. M.S. Saporito, E.M. Brown, M.S. Miller, and S. Carswell CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo J. Pharmacol. Exp. Ther. 288 1999 421 427
19. M. Shin, C. Yan, and D. Boyd An inhibitor of c-jun aminoterminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible 92-kDa type IV collagenase expression Biochim. Biophys. Acta 1589 2002 311 316
20. W. Wang, L. Shi, Y. Xie, C. Ma, W. Li, X. Su, S. Huang, R. Chen, Z. Zhu, Z. Mao, Y. Han, and M. Li SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease Neurosci. Res. 48 2004 195 202
21. J. Whitfield, S.J. Neame, L. Paquet, O. Bernard, and J. Ham Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release Neuron 29 2001 629 643